CAPItello-281
What it tests: Capivasertib plus abiraterone versus placebo plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. Updated overall survival results.

Listen to Oncology Here & Now
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletterWhat it tests: Capivasertib plus abiraterone versus placebo plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. Updated overall survival results.
EMBARKPETRANHADr. Gil MorganDr. Gil Morgan. Expert pick. October 21, 2025.
RC48-C016and 3 moreDr. Gil MorganDr. Gil Morgan. Daily round-up. Day 3. October 21, 2025.
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.